Fernández-Ortega P, Caloto MT, Chirveches E, Marquilles R, Francisco JS, Quesada A et al (2012) Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of life. Support Care Cancer 20:3141–3148. https://doi.org/10.1007/s00520-012-1448-1

Article  PubMed  Google Scholar 

Burke TA, Wisniewski T, Ernst FR (2011) Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer 19:131–140. https://doi.org/10.1007/s00520-009-0797-x

Article  PubMed  Google Scholar 

Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M et al (2016) Olanzapine for the Prevention of Chemotherapy-Induced nausea and vomiting. N Engl J Med 375:134–142. https://doi.org/10.1056/NEJMoa1515725

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T et al (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:242–249. https://doi.org/10.1016/S1470-2045(19)30678-3

Article  CAS  PubMed  Google Scholar 

Chow R, Herrstedt J, Aapro M, Chiu L, Lam H, Prsic E et al (2021) Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer 29:3439–3459. https://doi.org/10.1007/s00520-020-05935-7

Article  PubMed  PubMed Central  Google Scholar 

Ettinger DS, Huber S, Kris MG, Levy M, McNulty R, Noonan KR, Stucky-Marshall L, Urba S, Wood JG (1997) NCCN antiemesis practice guidelines. Oncol (Williston Park). 11A:57–89

Aapro M, Molassiotis A, Dicato M, Peláez I, Rodríguez-Lescure Á, Pastorelli D et al (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23:1986–1992. https://doi.org/10.1093/annonc/mds021

Article  CAS  PubMed  Google Scholar 

Abunahlah N, Sancar M, Dane F, Özyavuz MK (2016) Impact of adherence to antiemetic guidelines on the incidence of chemotherapy-induced nausea and vomiting and quality of life. Support Care Cancer 27:1139–1147. https://doi.org/10.1007/s00520-018-4403-y

Article  Google Scholar 

Woopen H, Richter R, Chekerov R, Inci G, Alavi S, Grabowski JP et al (2020) Prognostic role of chemotherapy-induced nausea and vomiting in recurrent Ovarian cancer patients: results of an individual participant data meta-analysis in 1213 support Care. Cancer 28:73–78. https://doi.org/10.1007/s00520-019-04778-1

Article  Google Scholar 

Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E et al (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27:v119. https://doi.org/10.1093/annonc/mdw270

Article  CAS  PubMed  Google Scholar 

Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA et al (2020) Antiemetics: ASCO Guideline Update. J Clin Oncol 38:2782–2797. https://doi.org/10.1200/JCO.20.01296

Article  CAS  PubMed  Google Scholar 

Ettinger DS, Berger MJ, Agarwal R, Anand S, Bagegni NA, Barbour S et al (2023) NCCN Guidelines Version 2. Antiemesis. https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf

Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94:1011–1015. https://doi.org/10.1038/sj.bjc.6603048

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jeong Y, Han HS, Lee HD, Yang J, Jeong J, Choi MK et al (2016) A pilot study evaluating Steroid-Induced Diabetes after antiemetic dexamethasone therapy in chemotherapy-treated Cancer patients. Cancer Res Treat 48:1429–1437. https://doi.org/10.4143/crt.2015.464

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nakamura M, Ishiguro A, Muranaka T, Fukushima H, Yuki S, Ono K et al (2017) A prospective observational study on Effect of Short-Term Periodic Steroid Premedication on Bone Metabolism in Gastrointestinal Cancer (ESPRESSO-01). Oncologist 22:592–600. https://doi.org/10.1634/theoncologist.2016-0308

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A et al (2018) Impact of baseline steroids on efficacy of programmed cell Death-1 and programmed death-ligand 1 blockade in patients with non-small-cell Lung Cancer. J Clin Oncol 36:2872–2878. https://doi.org/10.1200/JCO.2018.79.0006

Article  CAS  PubMed  Google Scholar 

Iorgulescu JB, Gokhale PC, Speranza MC, Eschle BK, Poitras MJ, Wilkens MK et al (2021) Concurrent dexamethasone limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. Clin Cancer Res 27:276–287. https://doi.org/10.1158/1078-0432.CCR-20-2291

Article  CAS  PubMed  Google Scholar 

Okada Y, Oba K, Furukawa N, Kosaka Y, Okita K, Yuki S et al (2019) One-day Versus three-day dexamethasone in combination with Palonosetron for the Prevention of Chemotherapy-Induced nausea and vomiting: a systematic review and individual Patient Data-based Meta-analysis. Oncologist 24:1593–1600. https://doi.org/10.1634/theoncologist.2019-0133

Article  CAS  PubMed  PubMed Central  Google Scholar 

Celio L, Bonizzoni E, Zattarin E, Codega P, de Braud F, Aapro M (2019) Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence. BMC Cancer 19:1268. https://doi.org/10.1186/s12885-019-6454-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Basch E, Becker C, Rogak LJ, Schrag D, Reeve BB, Spears P et al (2021) Composite grading algorithm for the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Clin Trials 18:104–114. https://doi.org/10.1177/1740774520975120

Article  PubMed  Google Scholar 

Tokunaga A, Sugiyama D, Maeda Y, Warner AB, Panageas KS, Ito S et al (2019) Selective inhibition of low-affinity memory CD8 + T cells by corticosteroids. J Exp Med 216:2701–2713. https://doi.org/10.1084/jem.20190738

Article  CAS  PubMed  PubMed Central  Google Scholar 

Janowitz T, Kleeman S, Vonderheide RH (2021) Reconsidering dexamethasone for Antiemesis when combining chemotherapy and immunotherapy. Oncologist 26:269–273. https://doi.org/10.1002/onco.13680

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dranitsaris G, Molassiotis A, Clemons M, Roeland E, Schwartzberg L, Dielenseger P et al (2017) The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol 28:1260–1267. https://doi.org/10.1093/annonc/mdx100

Article  CAS  PubMed  PubMed Central  Google Scholar 

Suzuki K, Yamanaka T, Hashimoto H, Shimada Y, Arata K, Matsui R et al (2016) Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Ann Oncol 27:1601–1606. https://doi.org/10.1093/annonc/mdw220

Article  CAS  PubMed  Google Scholar 

Ito Y, Tsuda T, Minatogawa H, Kano S, Sakamaki K, Ando M et al (2018) Placebo-Controlled, double-blinded phase III study comparing dexamethasone on Day 1 with dexamethasone on days 1 to 3 with combined Neurokinin-1 receptor antagonist and Palonosetron in High-Emetogenic Chemotherapy. J Clin Oncol 36:1000–1006. https://doi.org/10.1200/JCO.2017.74.4375

Article  CAS  PubMed  Google Scholar 

Sekine I, Segawa Y, Kubota K, Saeki T (2013) Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci 104:711–717. https://doi.org/10.1111/cas.12146

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K et al (2018) A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int J Clin Oncol 23:382–388doi. https://doi.org/10.1007/s10147-017-1200-4

Article  CAS  PubMed  Google Scholar 

Abe M, Hirashima Y, Kasamatsu Y, Kado N, Komeda S, Kuji S et al (2016) Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial. Support Care Cancer 24:675–682doi. https://doi.org/10.1007/s00520-015-2829-z

Article  PubMed  Google Scholar 

Basch E (2010) The missing voice of patients in drug-safety reporting. N Engl J Med 362:865–869. https://doi.org/10.1056/NEJMp0911494

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sarnes E, Crofford L, Watson M, Dennis G, Kan H, Bass D (2011) Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther 33:1413–1432. https://doi.org/10.1016/j.clinthera.2011.09.009

Article  PubMed  Google Scholar 

Papatheodoridis GV, Lekakis V, Voulgaris T, Lampertico P, Berg T, Chan HLY et al (2022) Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: a systematic review, meta-analysis, and expert opinion. J Hepatol 77:1670–1689. https://doi.org/10.1016/j.jhep.2022.07.003

Article  CAS  PubMed  Google Scholar 

Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, Tsao CJ et al (2003) Steroid-free chemotherapy decreases risk of Hepatitis B virus (HBV) reactivation in HBV-carriers with Lymphoma. Hepatology 37:1320–1328. https://doi.org/10.1053/jhep.2003.50220

Article  CAS  PubMed